Stoke Therapeutics CMO sells 5,545 shares on Sept. 1

Stoke Therapeutics, Inc. (STOK) reported that its Chief Medical Officer, Barry Ticho, sold a total of 5,545 shares of common stock on September 1, 2026 in open-market transactions under a Rule 10b5-1 trading plan adopted on November 19, 2025.

Rhea-AI Filing Summary

Stoke Therapeutics, Inc. (STOK) reported that its Chief Medical Officer, Barry Ticho, sold a total of 5,545 shares of common stock on September 1, 2026 in open-market transactions under a Rule 10b5-1 trading plan adopted on November 19, 2025. The sales were executed in multiple trades at weighted average prices within disclosed ranges.

Insider Trade Summary 10b5-1

Net Seller: 5,545 shares

Net Sell 2 txns

Insider Ticho Barry

Role CHIEF MEDICAL OFFICER

Sold 5,545 shs ($170K)

Type	Security	Shares	Price	Value
Sale	Common Stock F1, F2	3,945	$30.512	$120K
Sale	Common Stock F1, F3	1,600	$31.0569	$50K

Holdings After Transaction: Common Stock — 20,110 shares (Direct)

Footnotes (3)

1. F1. This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 19, 2025.
2. F2. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.94 to $30.92 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and in footnote 3 of this Form 4.
3. F3. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.96 to $31.20 per share, inclusive.

Key Figures

Shares sold (first transaction): 3,945 shares Weighted average sale price (first transaction): $30.512 per share Shares sold (second transaction): 1,600 shares +3 more

6 metrics

Shares sold (first transaction) 3,945 shares Common Stock sale on September 1, 2026

Weighted average sale price (first transaction) $30.512 per share 3,945-share sale; trades ranged from $29.94 to $30.92

Shares sold (second transaction) 1,600 shares Common Stock sale on September 1, 2026

Weighted average sale price (second transaction) $31.0569 per share 1,600-share sale; trades ranged from $30.96 to $31.20

Total shares sold 5,545 shares Aggregate of both reported sales on September 1, 2026

Rule 10b5-1 plan adoption date November 19, 2025 Plan governing the reported September 1, 2026 sales

Key Terms

Rule 10b5-1 trading plan, weighted average price, multiple transactions

3 terms

Rule 10b5-1 trading plan regulatory

"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

weighted average price financial

"The reported price in Column 4 is a weighted average price"

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

multiple transactions financial

"These shares were sold in multiple transactions at prices ranging"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Stoke Therapeutics (STOK) disclose for Barry Ticho?

Stoke Therapeutics disclosed that Chief Medical Officer Barry Ticho sold a total of 5,545 shares of common stock on September 1, 2026 in open-market transactions reported on Form 4.

How many STOK shares did Barry Ticho sell in each transaction?

Barry Ticho reported selling 3,945 shares of Stoke Therapeutics common stock at a weighted average price of $30.512 per share and an additional 1,600 shares at a weighted average price of $31.0569 per share on September 1, 2026.

Were Barry Ticho’s STOK share sales under a Rule 10b5-1 plan?

Yes. The Form 4 states that the September 1, 2026 sales were executed pursuant to a Rule 10b5-1 trading plan adopted by Barry Ticho on November 19, 2025, indicating the transactions were pre-arranged under that plan.

What price ranges applied to Barry Ticho’s STOK sales on September 1, 2026?

For the 3,945-share sale, the weighted average price of $30.512 reflects trades between $29.94 and $30.92 per share. For the 1,600-share sale, the weighted average price of $31.0569 reflects trades between $30.96 and $31.20 per share.

Does the Form 4 show Barry Ticho’s remaining STOK holdings after these sales?

No. For the September 1, 2026 transactions, the Form 4 does not provide a figure in the field that typically shows total shares owned following the transactions, so remaining holdings are not specified in this report.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/03/2026 - 04:29 PM EDT Accepted by SEC EDGAR 09/03/2026 - 04:17 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Ticho Barry

(Last) (First) (Middle)

C/O STOKE THERAPEUTICS, INC.

45 WIGGINS AVENUE

(Street)

BEDFORD MASSACHUSETTS 01730

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Stoke Therapeutics, Inc. [ STOK ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CHIEF MEDICAL OFFICER

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/01/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/01/2026		S(1)		3,945	D	$30.512(2)	21,710	D
Common Stock	09/01/2026		S(1)		1,600	D	$31.0569(3)	20,110	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 19, 2025.

2. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.94 to $30.92 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and in footnote 3 of this Form 4.

3. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.96 to $31.20 per share, inclusive.

	/s/ Jonathan Allan, Attorney-in-Fact	09/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)